Background: Drug-eluting stents (DES) have been shown to reduce the need for repeat revascularization compared with bare metal stents (BMS). However, there is little information regarding the safety and long-term efficacy of DES in patients with acute myocardial infarction (AMI).
Introduction
Routine stent implantation has a better procedural success rate and clinical outcome than balloon angioplasty in patients presenting with acute myocardial infarction (AMI). [1] [2] [3] However, restenosis and repeat revascularization remain significant clinical problems, limiting the long-term success of percutaneous coronary intervention. 1, 2, 4 Recently, drug-eluting stent (DES) implantation was shown to be effective in reducing restenosis compared with bare metal stent (BMS) implantation in elective patients, 5, 6 and DES implantation now comprises more than 80% of percutaneous coronary intervention in the United States. 7 Furthermore, worldwide DES use has grown rapidly in patients with AMI despite concerns about early thrombotic events and late restenosis. 8, 9 However, there is little information regarding the safety and efficacy of using DES in patients with AMI.
The present study is a retrospective analysis comparing clinical outcomes when using DES and BMS in consecutive patients with AMI.
Material and Methods

Patient Population
The study involved a total of 211 consecutive patients with AMI treated with DES within 7 days of symptom onset be- Stent implantation was performed using standard techniques. The postprocedural antithrombotic regimen consisted of a loading dose of clopidogrel (300 mg before intervention), lifelong aspirin (100 or 200 mg/day), and clopidogrel (75 mg/ day) for at least 1 month in patients with BMS and for at least 6 months in patients with DES.
Definition and Follow-Up
A major adverse cardiovascular event (MACE) was defined as death, nonfatal reinfarction, and target vessel revascularization (TVR). Reinfarction was diagnosed by recurrent symptoms and/or electrocardiographic changes in association with re-elevation of creatine kinase (CK)-MB and troponin-I levels greater than twice the upper normal limit. Target vessel revascularization was defined as a repeat intervention (surgical or percutaneous) driven by any lesion located in the same epicardial vessel treated at the index procedure. Thrombotic stent occlusion was angiographically documented as a complete occlusion (Thrombolysis in Myocardial Infarction [TIMI] grade 0 or 1) or flow-limiting thrombi (TIMI flow grade 1 or 2) in a previously successfully treated artery.
All demographic, clinical, angiographic, and procedural characteristics were prospectively entered into the Asan Medical Center angiographic database. During follow-up, recordings of all repeat interventions and clinical information were collected by chart review or telephone interview.
Statistical Analysis
Continuous variables are presented as mean ± standard deviation and were compared using independent t-tests. Categorical variables between the two groups were compared using chi-square or Fisher's exact tests. The cumulative incidence of adverse events was estimated according to the Kaplan-Meier method and compared using log rank tests. Variables found to be significant by univariate analysis were entered into multivariate analysis to identify independent predictors of adverse events. A p value < 0.05 was considered to indicate a significant difference.
Results
Baseline and Procedural Characteristics
Baseline clinical and angiographic characteristics are summarized in Tables I and II 
Clinical Outcomes
Clinical outcomes at 30 days and 1 year are presented in Table III . There was no significant difference between patients with DES and BMS in terms of the incidence of cardiac death, reinfarction, or TVR. Two patients with DES (0.9%) and two 201 patients with BMS (1.9%) experienced stent thrombosis within 30 days (p = 0.434). In addition, the incidence of MACE was also similar between the two groups at 30 days. In contrast, 1-year follow-up showed the incidence of MACE was significantly lower in patients with DES than in patients with BMS (6.6 vs. 14.0%, respectively, p = 0.011), mainly due to the lower TVR rate (4.3 vs. 9.9%, respectively, p = 0.028). Late stent thrombosis with subsequent reinfarction developed in two patients with BMS, but not in patients with DES. Major adverse cardiovascular event-free survival at 12 months was 93.4% in the DES and 86.0% in the BMS group (p = 0.028, by log rank test) (Fig. 1) . Multivariate analysis showed use of DES was a significant independent predictor of death, reinfarction, or repeat revascularization at 1 year (hazard ratio: 0.509, 95% confidence interval 0.299-0.867, p = 0.013).
Discussion
The present study showed that DES was safe in the treatment of AMI and had similar rates of procedural success, inhospital adverse events, and stent thrombosis compared with BMS. Furthermore, DES significantly reduced the incidence of major adverse events at 1 year despite the fact that patients with DES had more unfavorable baseline characteristics such as longer lesion length, shorter reference diameter, and smaller postprocedural minimal lesion diameter compared with patients with BMS. These results suggest that DES is superior to BMS in the treatment of AMI.
The thrombogenic coronary condition in patients with AMI 8 coupled with a theoretical tendency for hypercoagulability 9 and delayed re-endothelialization 10, 11 with DES, can potentially increase the risk of thrombotic complications and adversely affect outcomes after DES implantation during the acute phase of MI. However, regardless of these contradictory laboratory findings, we found there was no difference in stent thrombosis rates between patients with DES and BMS at 30 days and 1 year, nor in rates of MI or mortality. These findings are consistent with previous reports indicating that DES may be safe in the setting of AMI. [12] [13] [14] [15] Use of DES in patients with AMI resulted in reduced rates of MACE at 1 year (BMS vs. DES: 14.0 vs. 6.6; p = 0.011), mainly due to a lower TVR rate (BMS vs. DES: 9.6 vs. 4.3%; p = 0.028), similar to patients with stable ischemic syndrome. 16 Moreover, the TVR rate in patients with DES was almost unchanged from 8 months (3.8%) to 1 year (4.2%), whereas the TVR rate continued to increase during this period in patients with BMS (from 4.8 to 9.6%, respectively). The Rapamycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) study using sirolimus-eluting stents for AMI 12 and the subgroup analysis of the TAXUS-IV study of acute coronary syndrome 13 showed that DES implantation reduced the incidence of adverse events at 6 months to 1 year mainly due to a better TVR rate between 8 months to 1 year; this did not change for DES, as was the case in the present study. Thus, our results confirm that DES are effective in preventing repeat revascularization in the subset of unstable atherosclerotic lesions responsible for acute occlusions and suggest that further advantages of DES over BMS for AMI might be observed as follow-up durations increase.
In the present study, four patients with DES experienced MI, which occurred primarily within 30 days. In contrast, four with BMS experienced MI between 30 days and 1 year. The mortality rates were 1.3 and 0% for patients with BMS and DES, respectively. These mortality rates are considerably lower than those reported in other studies 12, 17, 18 which may reflect the inclusion of patients with NSTEMI and the exclusion of patients with cardiogenic shock on admission in the present study population. Other studies including patients with NSTE-MI and STEMI showed similar low rates of mortality. 14 
Limitations
There were several potential limitations to this study. First, it was a retrospective, nonrandomized, single-center registry study of DES implantation in AMI. Second, the choice of DES was left to the physician, leading to possible selection bias. Third, our findings were derived from a select population of patients with AMI, and it may not be possible to generalize our results to all patients with AMI. Despite these limitations, we believe this study demonstrates the safety and efficacy of DES in routine clinical practice for the treatment of AMI.
Conclusion
Drug-eluting stents for the treatment of acute myocardial infarction are safe and more effective in reducing the risk of major adverse events when compared with bare metal stents. However, further large-scale randomized trials will be needed to verify these promising initial results. 
